Trial Profile

Efficacy and Safety of Treatment Against Hepatitis C Virus Infection Based on Direct-acting Antivirals in Real-life Conditions: The GEHEP Cohort

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Boceprevir (Primary) ; Elbasvir/grazoprevir (Primary) ; Telaprevir (Primary) ; Daclatasvir; Elbasvir; Grazoprevir; Ledipasvir; Ombitasvir/paritaprevir/ritonavir; Simeprevir; Sofosbuvir; Velpatasvir
Indications Hepatitis C
Focus Adverse reactions; Therapeutic Use
Acronyms The GEHEP Cohort

Most Recent Events

08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
22 Jun 2022 Status changed from recruiting to completed.
11 Jun 2022 Results (N=644) assessing high efficacy of Glecaprevir/Pibrentasvir for HCV-Infected individuals with active drug use from two studies (NCT02057003 and NCT02333292) published in the Journal of Infection

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com